3Yu V L, Hansen D S, Ko W C, et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae blood- stream infections[J]. Emerging infectious diseases, 2007, 13(7).
4Ahmad T A, E1-Sayed L H, Haroun M, et al. Development of im- munization trials against Klebsiella pneumoniae[J]. Vaccine, 2012, 30(14): 2411-2420.
5Borer A, Saidel-Odes L, Eskira S, et al. Risk factors for develop- ing clinical infection with carbapenem-resistant Klebsiella pneu- moniae in hospital patients initially only colonized with carbape- nem-resistant K pneumoniae[J]. American Journal of Infection Control, 2012, 40(5): 421-425.
6Ktari S, Arlet G, Mnif B, et al. Emergence of muhidrug-resis- tant Klebsiella pneumoniae isolates producing VIM-4 metallo- 15-1actamase, CTX-M-15 extended-spectrum -lactamase, and CMY-g AmpC 13-1actamase in a Tunisian university hospital[J]. Antimicrobial agents and chemotherapy, 2006, 50(12): 4198- 42Ol.
